   
  
G/MA/QR/N/GBR/1/Add.2  
 
5 August  2022 
(22-5846) Page: 1/6 
Committee on Market Access  Original: English  
 
  
NOTIFICATION PURSUANT TO THE DECISION  ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
UNITED KINGDOM  
Addendum  
The following communication, dated 3 August  2022, is being circulated at the request of the 
delegation of the United Kingdom . 
 
A. Notifying Member: United Kingdom  
B. Date of notification: 3 August  2022 
C. First time notification:  
 Yes 
 No, last notification was made in (doc. symbol ): G/L/59/R ev.1  
D. Type of notification:  
 1. Complete (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in G/MA/QR/N/GBR/1  which are of the following nature : 
  2.1 Introduction of new restrictions, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a previously notified restriction, as describe d in Section 1. 
 3. Reverse notification of restrictions maintained by (Member ):  
E. The notification provides information for the following biennial period (e.g.  2012 -2014): 
2020-2022 and relates to restrictions in force as of 24 June 2022   
F. This notification contains information* relating to:  
 Section 1:  List of quantitative restrictions that are currently in force . 
 Section 2:  Cross -reference to other WTO notifications with information on quantitative restrictions 
that are currently in force and additional information . 
G. Comments of a general nature, including a description of the elimination of restrictions 
notified under D.2.2 and the date they ceased t o be in force.  
1. This addendum modifies and replaces QR No. 21 of G/MA/QR/N/GBR/1. This notification updates 
the list of commodity codes applicable to the medicines in scope and provides further information 
on the product descriptions.  
2. The UK is notifying the net reduction of 30 medicines from the list of medicines needed to support 
the treatment of UK patients at a time when COVID -19 is still having a real impact on both demand 
and supply of medicines, the export of which is subject to restriction in certain limited 
circumstances when those medicines are already in the UK supply chain and intended for UK 
patients.   
 
* In English  only. G/MA/QR/N/GBR/1/Add.2  
 
- 2 - 
 
  3. These are temporary measures in place to relieve critical shortages of medicines necessary for the 
protection of human heal th. Measures are reviewed regularly and only applied where the critical 
need cannot be met by alternative measures. On 15  December  2021, 47 medicines were removed 
from the list. As of 24 June 2022, a further 32 medicines were removed from the list. Two 
medicines have been added to the list.  
4. The UK 's notification G/MA/QR/N/GBR/1  included details relating to Northern Ireland. This 
notification does not amend those details which continue to apply.  
  
  G/MA/QR/N/GBR/1/Add.2  
 
- 3 - Section 1: List of quantitative restrictions that are currently in force  
 
QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
1 Measures to 
regulate exports of 
certain 
medicaments.  CP-X Medicines fall 
under the 
following 
commodity 
codes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3002.41.90 1. Heading 3002 - 
Classification  
Human blood;  animal 
blood prepared for 
therapeutic, 
prophylactic or 
diagnostic uses; 
antisera, other blood 
fractions and 
immunological products, 
whether or not modified 
or obtained by means of 
biotechnological 
processes; vaccines, 
toxins, cultures of 
micro -organisms 
(excluding yeasts) and 
similar products; cell 
cultures, whether or not 
modified  
 
 
 
Product Description per 
Commodity Code under 
Heading 3002  
 
Vaccines, toxins, 
cultures of micro -
organisms (excluding 
yeasts) and similar 
products , Other  Article XX(b) GATT  
Protection of human, 
animal or plant life or 
health.  
 Regulation 43(2) of 
the Human Medicines 
Regulations 2012 
requiring wholesale 
dealers to ensure 
continued supply of 
medicinal products so 
that the needs of 
patients in the UK are 
met. Further details 
can be found through: 
https://www.legislatio
n.gov.uk/uksi/2012/1
916/contents/made  
 
The date restrictions 
came into effect varies 
by medicine; this is 
specified for each 
medicine on  the list, 
updated on 
24 June 2022 and 
available  on gov.uk at  
 
https://assets.pub lishi
ng.service.gov.uk/gov
ernment/uploads/syst
em/uploads/attachme
nt_data/file/1042790/
restricted -medicines -
list-december -2021-
v3.csv/preview   
 
 The list of medicines 
is maintained by the 
Department of Health 
and Social Care.  
 
These measures are 
reviewed re gularly.  
A full change log of 
previous measures, 
from October 2019, 
can be found here:  
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk  
 
Medicines included 
on this list me et the 
following conditions:  
• The medicine is 
required to meet 
the needs of UK 
patients  
• The medicine is 
currently in 
shortage or risk 
of being in 
shortage  
• The export of 
the medicine 
would contribute 
to or exacerbate 
a shortage, or 
risk of shortage,  
  G/MA/QR/N/GBR/1/Add.2  
 
- 4 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
of that medicine 
in the UK  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3004.20.00  
 
 
 
 
 
 
3004.31.00  
 
 
 
3004.32.00  
 
 
 
 
 
3004.39.00  
 
 
 2. Heading 3004 - 
Classification  
Medicaments consisting 
of mixed or unmixed 
products for therapeutic 
or prophylactic uses, put 
up in measured doses 
(including those in the 
form of transdermal 
administration systems) 
or in forms or packings 
for retail sale  
 
Product Descripti on per 
Commodity Code under 
Heading 3004  
Other, containing 
antibiotics  
 
Other, containing 
hormones or other 
products of heading 
2937 
Containing insulin  
 
 
 
Containing 
corticosteroid 
hormones, their 
derivatives or structural 
analogues  
 
Other  
 
  
  Medicines on this list 
which have been 
produced to fulfil 
contracts overseas 
are not subject to  
restriction. As such, 
restrictions only 
apply to wholesaler 
dealer license 
holders that are not 
the market 
authorisation holder 
for a medicine 
intended for export. 
The measures are 
designed to ensure 
wholesalers fulfil 
their legal 
obligations to 
maintain supply to 
UK patients.  
 
These restrictions 
are only applied and 
maintained where  
alternative measures 
are not considered 
suffici ent on their 
own to ensure that 
UK supply meets 
demand.  
A number of 
exemptions apply to 
medicines in scope 
of these restrictions. 
For example, exports 
destined for  
  G/MA/QR/N/GBR/1/Add.2  
 
- 5 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
3004.49.00  
 
 
 
 
3004.90.00 Other, containing 
alkaloids or derivatives 
thereof , Other  
 
 
Other  
Further detail of these 
medicines can be found 
at  
https://www.gov.uk/gov
ernment/pu blications/m
edicines -that-cannot -be-
parallel -exported -from-
the-uk 
 
These restrictions apply 
in certain circumstances 
to exports of specified 
medicines which are 
placed on the UK 
market for UK patients 
and needed to protect 
human health, including 
to treat Covid -19, 
inter alia. 
 
 international 
humanitarian 
organisations such 
as COVAX are not 
covered. A full list of 
exemp tions can be 
found  at 
https://www.gov.uk/
government/publicati
ons/medicines -that-
cannot -be-parallel -
exported -from-the-
uk 
 
Requests for 
exemptions are 
considered on a 
case-by-case basis. 
These can be 
submitted by a 
foreign government  
or government 
agency, or a 
wholesaler on their 
behalf at 
restrictedmedicines
@dhsc.gov.uk    
 
Further information 
on these measures is 
available here:  
https://www .gov.uk/
guidance/parallel -
export -and-
hoarding -of-
restricted -medicines   
  G/MA/QR/N/GBR/1/Add.2  
 
- 6 - QR
No. General 
description of the 
restriction  Type of 
restriction  
 Tariff line 
code(s) 
affected, 
based on  
HS (2022) Detailed Product 
Description  WTO Justification 
and Grounds for 
Restriction, e.g., 
Other International 
Commitments  National legal basis 
and entry into force   
 Administration, 
modification of 
previously notified 
measures, and 
other comments  
1 2 3 4 5 6 7 
       It is the 
responsibility of the 
wholesaler to ensure 
any exports are 
made or withheld in 
compliance with 
these restrictions. 
Failure to comply 
with these 
restrictions may lead 
to regulatory action 
by the Medicines and 
Healthcare products 
Regulatory Authority 
(MHRA) against the 
wholesale dealer 's 
licence.  
There are no 
additional steps or 
declarations required 
from a customs 
perspective.  
 
__________  